Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y, Yoshida K, Kochi M, Sano T, Ichikawa W, Kakeji Y, Sunakawa Y, Takeuchi M, Fujii M.
Gastric Cancer. 2023 Aug 07. PMID: 37548812